News1

Advanced treatment successfully removed colorectal cancer spread to the peritoneum, targeting even invisible cancer cells.

HiDoc, operated by Daewoong Pharmaceutical's affiliate M Circle, launches global sites in English, Japanese, and Indonesian for market expansion.

Qurient accelerates global commercialization of dual payload antibody-drug conjugate platform developed with Lonza.

Osteom Pharma showcased premium oral care products at a global beauty expo in Dubai, targeting the Middle East and North Africa market.

Early detection and management of dementia focus on mild cognitive impairment, aided by government policies and advanced diagnostic techniques.

No one chooses their starting point in life; the state's role is to balance inequalities and provide support for recovery.

Democratic Party lawmaker Kim Kyo-heung is calling for a dedicated national suicide prevention fund, arguing that per-death spending on suicide prevention is just one-240th of traffic safety spending and urging coordinated support for vulnerable young people, including those facing isolation, addiction and mental health crises.

L&C Bio has secured import approval from the UAE’s Emirates Drug Establishment for its human tissue-based product Re2O, expanding its international footprint following regulatory approvals in Thailand and Peru and a supply agreement in the United States.

DongKoo Bio & Pharma’s biotech investments are showing progress across commercialization, clinical development and IPO preparations, with Quriant partnering with Lonza on an antibody-drug conjugate platform, D&D Pharmatech reporting Phase 2 results for a liver disease drug candidate, and Novacell Technology pursuing a Kosdaq listing.

Yipseel has received a decision to grant a South Korean patent for its low-immunogenicity universal induced pluripotent stem cell technology and plans to expand cell therapy development and clinical-grade cell line supply.

G2G Bio plans to introduce its InnoBioLAMP platform for ultra-high-concentration antibody formulations at PODD 2026, aiming to make subcutaneous administration more convenient and expand partnerships with global pharmaceutical companies.

VAIM launched its Juvelook skincare products in China, expanding its market presence after receiving medical device approval.

Wontech secures CE MDR certification for three core products, aiming to expand into the European market and boost overseas growth.

AITRICS has been named one of the world's top health tech companies by TIME and Statista, receiving an Outstanding rating in AI and data analysis.